Literature DB >> 3928388

Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease.

R J Shirkey, L B Jellett, D C Kappatos, T J Maling, A Macdonald.   

Abstract

Sodium valproate at a concentration of 300 mumol/l in whole blood, partitioned between the red blood cell and plasma to produce a red blood cell/plasma partition ratio of 0.20. Red blood cell uptake was proportional to percent free drug in plasma and uptake was maximal when plasma was replaced by buffer, producing a red blood cell/buffer ratio of 0.87. Reduction of plasma protein binding by plasma dilution, by increasing the total sodium valproate plasma concentration, or by renal or hepatic disease in 24 patients, caused a predictable rise in red blood cell uptake of drug. The red blood cell represented a relatively small compartment for free sodium valproate in blood, however uptake of the drug into this compartment increased considerably in states of reduced plasma protein binding. Because the concentration of drug in the red blood cell reflects free drug concentration in plasma, the red blood cell may serve as an indicator of free drug changes in blood.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928388     DOI: 10.1007/bf00544365

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  The distribution of quinidine in human blood.

Authors:  I E Hughes; K F Ilett; L B Jellett
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

Review 2.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

Review 3.  Plasma concentrations in the control of drug therapy.

Authors:  L B Jellett
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  Correlation between red cell and free plasma phenytoin levels in renal disease.

Authors:  A L Sherwin; C D Harvey; I E Leppik; A Gonda
Journal:  Neurology       Date:  1976-09       Impact factor: 9.910

5.  Protein binding of valproic acid in uremic patients.

Authors:  J Bruni; L H Wang; T C Marbury; C S Lee; B J Wilder
Journal:  Neurology       Date:  1980-05       Impact factor: 9.910

6.  Valproate plasma protein binding in the uremic condition.

Authors:  D Brewster; N C Muir
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

7.  The influence of various factors in the in vitro distribution of haloperidol in human blood.

Authors:  I E Hughes; L B Jellett; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

8.  Steady-state kinetics of valproic acid in epileptic patients.

Authors:  J Bruni; B J Wilder; L J Willmore; R J Perchalski; H J Villarreal
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

9.  Disposition of valproic acid in man.

Authors:  R Gugler; A Schell; M Eichelbaum; W Fröscher; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

10.  Determination of unbound valproic acid concentration in plasma by equilibrium dialysis and gas--liquid chromatography: methodological aspects and observations in epileptic patients.

Authors:  R Riva; F Albani; A Baruzzi; I Galvani; E Perucca
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

View more
  6 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Erythrocytes and the transport of drugs and endogenous compounds.

Authors:  M S Highley; E A De Bruijn
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

3.  Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.

Authors:  M E Veronese; S McLean; R Hendriks
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

4.  Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy.

Authors:  L Herngren; A Nergårdh
Journal:  J Neurol       Date:  1988-11       Impact factor: 4.849

5.  Clinical validation and implications of dried blood spot sampling of carbamazepine, valproic acid and phenytoin in patients with epilepsy.

Authors:  Sing Teang Kong; Shih-Hui Lim; Wee Beng Lee; Pasikanthi Kishore Kumar; Hwee Yi Stella Wang; Yan Lam Shannon Ng; Pei Shieen Wong; Paul C Ho
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

Review 6.  Chronopharmacology of anti-convulsive therapy.

Authors:  Sriram Ramgopal; Sigride Thome-Souza; Tobias Loddenkemper
Journal:  Curr Neurol Neurosci Rep       Date:  2013-04       Impact factor: 5.081

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.